Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SAR 442970

Next Previous
X
Search
Drug Profile

SAR 442970

Alternative Names: Anti-TNFa and OX40L - Sanofi; Anti-TNFa/OX40L - Sanofi; NANOBODY®; SAR-442970; VHH antibody

Latest Information Update: 02 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanofi
  • Class Anti-inflammatories; Monoclonal antibodies; Single-domain antibodies; Skin disorder therapies
  • Mechanism of Action OX40 ligand inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Hidradenitis suppurativa
  • Phase I Inflammation

Most Recent Events

  • 15 Jul 2024 Sanofi plans the phase IIa RESULT trial for Focal segmental glomerulosclerosis (In adolescents, In adults, In the elderly) in September 2024 (NCT06500702)
  • 15 Jun 2023 Phase-II clinical trials in Hidradenitis suppurativa (In adults, In the elderly) in Canada (Parenteral) (NCT05849922) (EudraCT2022-502370-17-00)
  • 02 May 2023 Sanofi plans the phase II HS OBTAIN trial for Hidradenitis suppurativa (In adults, In the elderly) (Parenteral) (NCT05849922) (EudraCT2022-502370-17-00)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top